In Suk C. Bullock

Array ( [id] => 9902022 [patent_doc_number] => 20150057222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'METHODS OF TREATING CARTILAGE DEFECTS USING A SOLUBLE MORPHOGENIC PROTEIN COMPLEX' [patent_app_type] => utility [patent_app_number] => 14/197952 [patent_app_country] => US [patent_app_date] => 2014-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 24412 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14197952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9634316 [patent_doc_number] => 20140212424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 14/194090 [patent_app_country] => US [patent_app_date] => 2014-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 26088 [patent_no_of_claims] => 80 [patent_no_of_ind_claims] => 59 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14194090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9537169 [patent_doc_number] => 20140161816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-12 [patent_title] => 'ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES' [patent_app_type] => utility [patent_app_number] => 14/068010 [patent_app_country] => US [patent_app_date] => 2014-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 41926 [patent_no_of_claims] => 101 [patent_no_of_ind_claims] => 41 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14068010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10169347 [patent_doc_number] => 09200048 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-01 [patent_title] => 'High activity growth factor mutants' [patent_app_type] => utility [patent_app_number] => 14/182604 [patent_app_country] => US [patent_app_date] => 2014-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8594 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14182604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9685307 [patent_doc_number] => 20140242071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-28 [patent_title] => 'M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/171330 [patent_app_country] => US [patent_app_date] => 2014-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 49322 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14171330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311736 [patent_doc_number] => 20160347846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'FUSION PROTEINS FOR MODULATING REGULATORY AND EFFECTOR T CELLS' [patent_app_type] => utility [patent_app_number] => 14/764024 [patent_app_country] => US [patent_app_date] => 2014-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 26155 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14764024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9635418 [patent_doc_number] => 20140213528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'Fibrosuppressant Biotherapeutics' [patent_app_type] => utility [patent_app_number] => 14/168900 [patent_app_country] => US [patent_app_date] => 2014-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 11311 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14168900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10567419 [patent_doc_number] => 09290576 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => 'Antibodies that bind to TL1A and their uses' [patent_app_type] => utility [patent_app_number] => 14/146566 [patent_app_country] => US [patent_app_date] => 2014-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 9 [patent_no_of_words] => 31544 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14146566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9602716 [patent_doc_number] => 20140199399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA' [patent_app_type] => utility [patent_app_number] => 14/139332 [patent_app_country] => US [patent_app_date] => 2013-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 12216 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14139332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10444599 [patent_doc_number] => 20150329613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-19 [patent_title] => 'FUSION POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/655617 [patent_app_country] => US [patent_app_date] => 2013-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13514 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14655617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430222 [patent_doc_number] => 20150315234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'MYOBLAST DIFFERENTIATION PROMOTER' [patent_app_type] => utility [patent_app_number] => 14/382700 [patent_app_country] => US [patent_app_date] => 2013-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3732 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14382700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11487087 [patent_doc_number] => 09593151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Use of fusion protein' [patent_app_type] => utility [patent_app_number] => 14/653276 [patent_app_country] => US [patent_app_date] => 2013-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 7638 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14653276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9561888 [patent_doc_number] => 20140179601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'FGF-9 AND ITS USE RELATING TO BLOOD VESSELS' [patent_app_type] => utility [patent_app_number] => 14/093000 [patent_app_country] => US [patent_app_date] => 2013-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13020 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 37 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14093000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11611539 [patent_doc_number] => 09649383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Liquid formulations for TNFR:Fc fusion proteins' [patent_app_type] => utility [patent_app_number] => 14/443557 [patent_app_country] => US [patent_app_date] => 2013-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 16555 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14443557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9739767 [patent_doc_number] => 20140275486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/078181 [patent_app_country] => US [patent_app_date] => 2013-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14416 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14078181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9397009 [patent_doc_number] => 20140094416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'SPARC ANGIOGENIC DOMAIN AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/078119 [patent_app_country] => US [patent_app_date] => 2013-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15535 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14078119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10110824 [patent_doc_number] => 09146232 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-29 [patent_title] => 'Method for stabilizing protein' [patent_app_type] => utility [patent_app_number] => 14/071584 [patent_app_country] => US [patent_app_date] => 2013-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4704 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14071584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10399432 [patent_doc_number] => 20150284441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'TGFBeta-derived polypeptides and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/440627 [patent_app_country] => US [patent_app_date] => 2013-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5697 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14440627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9569173 [patent_doc_number] => 20140186887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'RECEPTOR ACTIVATOR OF NF-kappaB' [patent_app_type] => utility [patent_app_number] => 14/065133 [patent_app_country] => US [patent_app_date] => 2013-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 27893 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14065133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11698854 [patent_doc_number] => 09688757 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'Bi-specific affinity reagents for cell-lineage-specific TNF-alpha neutralization' [patent_app_type] => utility [patent_app_number] => 14/438288 [patent_app_country] => US [patent_app_date] => 2013-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 18 [patent_no_of_words] => 13936 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14438288 [rel_patent_id] =>[rel_patent_doc_number] =>)